Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cell killing and mutation induction by heavy ion beams.

N Shigematsu1, N Ihara, T Kawata

  • 1Department of Radiology, Keio University, School of Medicine, Shinjuku-ku, Tokyo 160-8582, Japan. shige@rad.med.keio.ac.jp

International Journal of Molecular Medicine
|April 11, 2001
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Use of the Rash Appearance to Distinguish Cholinergic Urticaria Subtypes: A Retrospective Cohort Study.

American journal of clinical dermatology·2025
Same author

Improvement of redness and hyperkeratosis in a case of Nagashima-type palmoplantar keratosis during Tofacitinib treatment for ulcerative colitis.

Journal of the European Academy of Dermatology and Venereology : JEADV·2022
Same author

Cholesterol 25-hydroxylase is a metabolic switch to constrain T cell-mediated inflammation in the skin.

Science immunology·2021
Same author

Linear and disseminated porokeratosis in one family showing identical and independent second hits in MVD among skin lesions, respectively: a proof-of-concept study.

The British journal of dermatology·2021
Same author

A case of type 1 segmental Darier disease showing widespread Blaschkoid skin lesions with p.P160L mutation in ATP2A2.

Journal of the European Academy of Dermatology and Venereology : JEADV·2020
Same author

An adult case of X-linked chronic granulomatous disease with skin ulcer on the nose and internal canthus.

Journal of the European Academy of Dermatology and Venereology : JEADV·2020

Heavy ion beams, including carbon and neon, show significant radiobiological effects on cancer cells. Neon beams may be more suitable for heavy ion therapy, especially with fractionation to reduce mutations.

Area of Science:

  • Radiation oncology
  • Radiobiology
  • Cancer research

Background:

  • Carbon beam radiotherapy, utilized in Japan since 1994, necessitates a deeper understanding of heavy ion radiobiological effects.
  • Investigating the comparative efficacy of different heavy ion types and their physical parameters is crucial for optimizing cancer treatment.

Purpose of the Study:

  • To elucidate the radiobiological effects of carbon and neon ion beams on human cancer cell lines and V79 cells.
  • To compare the cytotoxic and mutagenic potential of carbon and neon beams at varying Linear Energy Transfer (LET) levels.

Main Methods:

  • Human cancer cell lines (RMG-1, MDA-MB231) and V79 cells were irradiated with carbon (20 or 80 keV/microm) or neon beams (80 keV/microm).
  • Cell killing was assessed using colony formation assays.

Related Experiment Videos

  • Mutation induction was quantified via the hprt locus mutation assay, counting 6-thioguanine resistant colonies.

    • Main Results:

    • Higher LET carbon beams (80 keV/microm) exhibited enhanced cytotoxic effects compared to lower LET beams (20 keV/microm).
    • Carbon beams showed a slightly greater cytotoxic effect than neon beams at the same LET (80 keV/microm), though not significantly.
    • Heavy ion irradiation resulted in a significantly higher mutant fraction than X-ray irradiation, increasing with carbon beam LET.
    • Neon beams yielded a lower mutant fraction than carbon beams at equivalent LET values.
    • Fractionation of carbon beam irradiation did not impact cell survival but reduced the mutant fraction.

    Conclusions:

    • Neon beams may be preferable for heavy ion therapy, particularly at higher doses, due to potentially lower mutagenicity.
    • Fractionated heavy ion beam administration could be a strategy to mitigate treatment-induced mutations, enhancing therapeutic safety.